Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-Abdominal Infection - Full Text View

Sponsor:	Wyeth
Information provided by:	Wyeth
ClinicalTrials.gov Identifier:	NCT00195351

Purpose

This is a phase 3b/4 randomized, open-label, comparative, multicenter study of the safety and efficacy of tigecycline to ceftriaxone sodium plus metronidazole in hospitalized subjects with cIAI (Complicated Intra-Abdominal Infection). Subjects with clinical signs and symptoms of cIAI will be included for enrollment. Subjects will be stratified at randomization for Acute Physiologic and Chronic Health Evaluation scale (APACHE II) score < 10 and > 10. Subjects will be followed for efficacy through the test-of-cure assessment. Safety evaluations will occur through the treatment and post-treatment periods and continue through resolution or stability of the adverse event(s).

Condition	Intervention	Phase
Appendicitis Cholecystitis Cross Infection Diverticulitis Peritonitis	Drug: tigecycline Drug: ceftriaxone sodium + metronidazole	Phase IV

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study
Official Title:	A Multicenter, Open-Label, Randomized Comparative Study of Tigecycline vs Ceftriaxone Sodium Plus Metronidazole for the Treatment of Hospitalized Subjects With Complicated Intra-Abdominal Infection

Resource links provided by NLM:

MedlinePlus related topics: Appendicitis Diverticulosis and Diverticulitis

Drug Information available for: Metronidazole hydrochloride Metronidazole phosphate Ceftriaxone Ceftriaxone Sodium Tigecycline Metronidazole

U.S. FDA Resources

Further study details as provided by Wyeth:

Primary Outcome Measures:

Clinical Response in the Clinically Evaluable Population at the Test-of-Cure Visit. [ Time Frame: 10-21 days after the last dose of test article ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Clinical Response in the Microbiologically Evaluable Population [ Time Frame: 10-21 days after the last dose of test article ] [ Designated as safety issue: No ]
Microbiological Response (Eradication Rate at the Subject Level) [ Time Frame: 10-21 days after the last dose of test article ] [ Designated as safety issue: No ]

Enrollment:	467
Study Start Date:	September 2005
Study Completion Date:	February 2008
Primary Completion Date:	February 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
A: Active Comparator	Drug: tigecycline every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)
B: Active Comparator	Drug: ceftriaxone sodium + metronidazole Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the discretion of the investigator.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Clinical diagnosis of complicated intra-abdominal infection that requires surgery within 24 hours.
Fever over 100.4°F (38.0°C) or high white blood cell count plus other symptoms such as nausea, vomiting, abdominal pain.

Exclusion Criteria:

Cancer
Medicines that suppress the immune system
Dialysis

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00195351

Show 67 Study Locations

Sponsors and Collaborators

Wyeth

Investigators

Study Director:

Medical Monitor

Wyeth

More Information

No publications provided

Responsible Party:	Wyeth ( Wyeth (Registry Contact: Clinical Trial Registry Specialist) )
Study ID Numbers:	3074A1-400
Study First Received:	September 12, 2005
Results First Received:	February 27, 2009
Last Updated:	April 16, 2009
ClinicalTrials.gov Identifier:	NCT00195351 History of Changes
Health Authority:	Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica; Brazil: National Committee of Ethics in Research; Canada: Health Canada; Chile: Instituto de Salud Publica de Chile; Mexico: National Council of Science and Technology; United States: Institutional Review Board

Keywords provided by Wyeth:

Complicated intra-abdominal infection
Appendicitis with abscess
Perforated diverticulitis
Purulent peritonitis
Complicated cholecystitis

Additional relevant MeSH terms:

Gallbladder Diseases
Communicable Diseases
Metronidazole
Anti-Infective Agents
Antiprotozoal Agents
Gastrointestinal Diseases
Tigecycline
Physiological Effects of Drugs
Infection
Diverticulitis
Anti-Bacterial Agents
Antiparasitic Agents
Pathologic Processes
Acalculous Cholecystitis

Appendicitis
Biliary Tract Diseases
Therapeutic Uses
Peritoneal Diseases
Cross Infection
Peritonitis
Cholecystitis
Ceftriaxone
Intestinal Diseases
Pharmacologic Actions
Cecal Diseases
Digestive System Diseases
Radiation-Sensitizing Agents
Gastroenteritis

ClinicalTrials.gov processed this record on November 09, 2009